利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

101 条记录 (耗时 0.032 秒)

    Developing apparatus using toner with conductive particles
    22.
    发明授权
    Developing apparatus using toner with conductive particles 失效
    显影装置使用带导电颗粒的调色剂

    公开(公告)号：US06594462B2

    公开(公告)日：2003-07-15

    申请号：US09803968

    申请日：2001-03-13

    申请人： Yasuyuki Ishii ,  Tomomi Kakeshita

    发明人： Yasuyuki Ishii ,  Tomomi Kakeshita

    IPC分类号： G03G1508

    CPC分类号： G03G9/0827 ,  G03G9/0825 ,  G03G9/09708 ,  G03G15/0806 ,  G03G15/0812 ,  G03G2215/0634

    摘要： A developing apparatus, which can obtain a stable toner charging amount even if a developer charging member is contaminated by toner and reduce reversal fog to reduce toner consumption, has a developer carrying body for carrying a developer to a developing position, and a developer charging member contacted with the developer to charge the developer, wherein the developer includes toner and conductive particles.

    摘要翻译： 即使显影剂充电构件被调色剂污染并且减少反转雾以减少调色剂消耗量，也可以获得稳定的调色剂充电量的显影装置具有用于将显影剂携带到显影位置的显影剂承载体和显影剂充电构件 与显影剂接触以对显影剂充电，其中显影剂包括调色剂和导电颗粒。

    Spiro compounds
    23.
    发明授权
    Spiro compounds 失效
    螺环化合物

    公开(公告)号：US06462053B1

    公开(公告)日：2002-10-08

    申请号：US10101221

    申请日：2002-03-20

    申请人： Takehiro Fukami ,  Akio Kanatani ,  Akane Ishihara ,  Yasuyuki Ishii ,  Toshiyuki Takahashi ,  Yuji Haga ,  Toshihiro Sakamoto ,  Takahiro Itoh

    发明人： Takehiro Fukami ,  Akio Kanatani ,  Akane Ishihara ,  Yasuyuki Ishii ,  Toshiyuki Takahashi ,  Yuji Haga ,  Toshihiro Sakamoto ,  Takahiro Itoh

    IPC分类号： A61K34355

    CPC分类号： C07D405/12 ,  C07D213/61 ,  C07D307/94 ,  C07D471/10 ,  C07D491/10

    摘要： A method for treating a cardiovascular disorder, which involves administering to a patient in need a therapeutically effective amount of a compound of formula (I): wherein Ar1 represents an aryl or heteroaryl which may be substituted, the substituent being selected from the group consisting of halogen, nitro, lower alkyl, halo(lower) alkyl, hydroxy(lower) alkyl, cyclo(lower) alkyl, lower alkenyl, lower alkoxy, halo(lower) alkoxy, lower alkylthio, carboxyl, lower alkanoyl, lower alkoxycarbonyl, lower alkylene optionally substituted with oxo, and a group represented by the formula —Q—Ar2; Ar2 represents an aryl or heteroaryl which may be substituted, the substituent being selected from the group consisting of halogen, cyano, lower alkyl, halo(lower) alkyl, hydroxy(lower) alkyl, hydroxy, lower alkoxy, halo(lower) alkoxy, lower alkylamino, di-lower alkylamino, lower alkanoyl and aryl: n represents 0 or 1; Q represents a single bond or carbonyl; T, U, V and W each independently represent a nitrogen atom or a methine group which may have a substituent selected from the group consisting of halogen, lower alkyl, hydroxy and lower alkoxy, wherein at least two of which represent said methine group; X represents methine; Y represents an imino which may be substituted with lower alkyl, or oxygen; or a salt or ester thereof.

    摘要翻译： 一种治疗心血管疾病的方法，其涉及向需要的患者施用治疗有效量的式（I）化合物：其中Ar1表示可被取代的芳基或杂芳基，所述取代基选自 卤素，硝基，低级烷基，卤代（低级）烷基，羟基（低级）烷基，环（低级）烷基，低级烯基，低级烷氧基，卤代（低级）烷氧基，低级烷硫基，羧基，低级烷酰基，低级烷氧基羰基， 任选被氧代取代的基团和由式-Q-Ar 2表示的基团; Ar 2表示可被取代的芳基或杂芳基，所述取代基选自卤素，氰基，低级烷基，卤代（低级）烷基， 羟基（低级）烷基，羟基，低级烷氧基，卤代（低级）烷氧基，低级烷基氨基，二低级烷基氨基，低级烷酰基和芳基：n表示0或1; Q表示单键或羰基; T，U， W各自独立地表示硝基 可以具有选自卤素，低级烷基，羟基和低级烷氧基的取代基的次甲基，其中至少两个表示所述次甲基; X表示次甲基; Y表示可以被取代的亚氨基 与低级烷基或氧; 或其盐或酯。

    Charging apparatus and image forming apparatus
    26.
    发明授权
    Charging apparatus and image forming apparatus 失效
    充电装置及成像装置

    公开(公告)号：US5799233A

    公开(公告)日：1998-08-25

    申请号：US710998

    申请日：1996-09-26

    申请人： Yasuyuki Ishii ,  Hiroyuki Adachi ,  Hiroki Kisu ,  Hiroaki Ogata

    发明人： Yasuyuki Ishii ,  Hiroyuki Adachi ,  Hiroki Kisu ,  Hiroaki Ogata

    IPC分类号： G03G15/02 ,  G03G21/18

    CPC分类号： G03G15/0241 ,  G03G2215/022

    摘要： A charging apparatus includes a charging member contactable or proximatable to a member to be charged, the charging member being capable of being supplied with a voltage; wherein the charging member has a magnetic particle layer, and a magnetic force generator with a gap for generating magnetic force in the magnetic particles, the magnetic particle layer and magnetic force generator forming a magnetic circuit; and wherein the magnetic particle has a particle size of no less than 10 .mu.m and no more than 100 .mu.m, and the maximum magnetic flux density in the gap ranges 1,000.times.10.sup.-4 T-10,000.times.10.sup.-4 T.

    摘要翻译： 充电装置包括可充电或可接近待充电构件的充电构件，充电构件能够被提供电压; 其中所述充电构件具有磁性颗粒层，以及具有用于在所述磁性颗粒中产生磁力的间隙的磁力发生器，所述磁性颗粒层和磁力发生器形成磁路; 并且其中所述磁性颗粒具有不小于10μm且不大于100μm的粒径，并且所述间隙中的最大磁通密度范围为1,000×10 -4 T-10,000×10 -4 T。

    Therapeutic agent for malignant tumors expressing MHC class II
    28.
    发明授权
    Therapeutic agent for malignant tumors expressing MHC class II 有权
    表达MHC II类恶性肿瘤的治疗剂

    公开(公告)号：US09303083B2

    公开(公告)日：2016-04-05

    申请号：US13877844

    申请日：2011-10-04

    申请人： Shuji Matsuoka ,  Yasuyuki Ishii

    发明人： Shuji Matsuoka ,  Yasuyuki Ishii

    IPC分类号： C07K16/28 ,  C07K16/18 ,  C07K16/30

    CPC分类号： C07K16/18 ,  C07K16/2803 ,  C07K16/30 ,  C07K2317/34 ,  G01N2333/70539

    摘要： Provided is a novel therapeutic agent specific for a malignant tumor expressing MHC class II. The present invention provides an antibody recognizing a protein constituting MHC class II expressed on a malignant tumor, the antibody comprising at least one selected from heavy chain CDR1 (amino acid sequence represented by positions 49 to 54 of SEQ ID NO: 54), heavy chain CDR2 (amino acid sequence represented by positions 69 to 84 of SEQ ID NO: 54), heavy chain CDR3 (amino acid sequence represented by positions 117 to 128 of SEQ ID NO: 54), light chain CDR1 (amino acid sequence represented by positions 46 to 55 of SEQ ID NO: 56), light chain CDR2 (amino acid sequence represented by positions 71 to 77 of SEQ ID NO: 56), and light chain CDR3 (amino acid sequence represented by positions 100 to 108 of SEQ ID NO: 56).

    摘要翻译： 提供一种特异于表达II类MHC的恶性肿瘤的新型治疗剂。 本发明提供一种抗体，其识别构成在恶性肿瘤上表达的II类MHC的蛋白质，所述抗体包含选自重链CDR1（SEQ ID NO：54的49至54位的氨基酸序列）中的至少一种，重链 CDR2（SEQ ID NO：54的第69〜84位的氨基酸序列），重链CDR3（SEQ ID NO：54的117〜128位的氨基酸序列），轻链CDR1（由位置 SEQ ID NO：56的46〜55），轻链CDR2（由SEQ ID NO：56的71〜77位表示的氨基酸序列）和轻链CDR3（SEQ ID NO： ：56）。

    Image forming apparatus
    29.
    发明授权
    Image forming apparatus 有权
    图像形成装置

    公开(公告)号：US08948638B2

    公开(公告)日：2015-02-03

    申请号：US13215700

    申请日：2011-08-23

    申请人： Yuji Ishikura ,  Yasuyuki Ishii ,  Hideki Kosugi ,  Tetsuro Hirota ,  Masaaki Yamada ,  Yoshiko Ogawa ,  Atsushi Kurokawa ,  Hideyasu Seki ,  Masanori Horike ,  Shin Kayahara

    发明人： Yuji Ishikura ,  Yasuyuki Ishii ,  Hideki Kosugi ,  Tetsuro Hirota ,  Masaaki Yamada ,  Yoshiko Ogawa ,  Atsushi Kurokawa ,  Hideyasu Seki ,  Masanori Horike ,  Shin Kayahara

    IPC分类号： G03G15/06 ,  G03G15/08 ,  G03G15/01 ,  G03G15/16

    CPC分类号： G03G15/0131 ,  G03G15/0189 ,  G03G15/1605

    摘要： An image forming apparatus includes a latent image carrier; a latent image writer to write a latent image on the latent image carrier; a developing unit including a toner carrier having first and second electrodes insulated via an insulator member and a voltage applying unit to apply voltages to the first and second electrodes having a potential difference to generate first electric fields to cause the toner to hop from the toner carrier to the latent image carrier to develop a toner image; and a transfer unit to transfer the developed toner image to a transferring member. When alternating voltages having a same phase and same amplitude are applied to the first and second electrodes to form second electric fields between the latent image carrier and the toner carrier, the toner is discharged from the toner carrier to the latent image carrier in a toner discharge mode.

    摘要翻译： 图像形成装置包括潜像载体; 潜像写入器，用于在潜像载体上写入潜像; 显影单元，包括具有通过绝缘体构件绝缘的第一和第二电极的调色剂载体和施加电压的电压施加到具有电位差的第一和第二电极，以产生第一电场，以使调色剂从调色剂载体 到潜像载体以形成调色剂图像; 以及将显影的调色剂图像转印到转印部件的转印单元。 当具有相同相位和相同振幅的交变电压施加到第一和第二电极以在潜像载体和调色剂载体之间形成第二电场时，调色剂在调色剂排出物中从调色剂载体排出到潜像载体 模式。

    Method for quantification of antigen-specific canine IgE
    30.
    发明授权
    Method for quantification of antigen-specific canine IgE 有权
    抗原特异性犬IgE定量方法

    公开(公告)号：US08716031B2

    公开(公告)日：2014-05-06

    申请号：US12992476

    申请日：2009-05-12

    申请人： Kenichi Masuda ,  Yasuyuki Ishii ,  Nobutaka Yasuda

    发明人： Kenichi Masuda ,  Yasuyuki Ishii ,  Nobutaka Yasuda

    IPC分类号： C07K16/06 ,  C07K16/42 ,  G01N33/53 ,  G01N33/536 ,  G01N33/537 ,  G01N33/543 ,  G01N33/563 ,  G01N33/96 ,  G01N33/68 ,  C12N5/20 ,  C12N5/16

    CPC分类号： G01N33/6854 ,  C07K16/06 ,  C07K16/42 ,  C07K16/4291 ,  C07K2317/33 ,  C12N5/163 ,  G01N33/536 ,  G01N33/537 ,  G01N33/543 ,  G01N33/96 ,  G01N2333/435 ,  G01N2469/20 ,  G01N2496/05 ,  G01N2800/24 ,  Y10S435/975 ,  Y10T436/10 ,  Y10T436/106664

    摘要： Disclosed is a convenient and effective means for quantifying an antigen-specific canine or human IgE. Specifically disclosed is a method for quantifying an antigen-specific canine IgE, which comprises the following steps (A) to (D): (A) contacting a biological sample collected from a subject with an antigen to conjugate IgE contained in the sample with the antigen; (B) measuring the quantity of IgE in a standard sample collected from an experimental animal which is different from the subject and has been sensitized with the same antigen as that used in step (A) by using a substance capable of recognizing both IgE from the subject and IgE from the experimental animal, thereby producing a standard curve; (C) detecting a conjugate formed in step (A) by using the same substance capable of recognizing both IgE from the subject and IgE from the experimental animal as that used in step (B); and (D) determining the quantity of IgE in the biological sample collected from the subject by utilizing the quantity of the conjugate detected in step (C) and the standard curve produced in step (B). Also specifically disclosed is a method for quantifying an antigen-specific human IgE.

    摘要翻译： 公开了用于定量抗原特异性犬或人IgE的方便和有效的方法。 具体公开的是定量抗原特异性犬IgE的方法，其包括以下步骤（A）至（D）：（A）使从受试者收集的生物样品与抗原接触，将样品中含有的IgE与 抗原; （B）测量从与受试者不同的实验动物收集的标准样品中的IgE的量，并且已经用与步骤（A）中使用的相同的抗原致敏，通过使用能够识别来自 受试者和IgE，从而产生标准曲线; （C）通过使用能够从受试者中识别出两种IgE的相同物质和步骤（B）中使用的实验动物的IgE，检测步骤（A）中形成的缀合物; 和（D）通过利用在步骤（C）中检测到的共轭物的量和步骤（B）中产生的标准曲线来确定从受试者收集的生物样品中的IgE的量。 还具体公开了一种定量抗原特异性人IgE的方法。